BioSpace News Archive

MedMira Inc. (MedMira) (TSXV: MIR), reported today on its financial results for the quarter ended April 30, 2022.

Ascentage Pharma announced that its novel inhibitor of the embryonic ectoderm development protein, APG-5918, has been cleared by the US Food and Drug Administration to enter a first-in-human study that will assess the safety, pharmacokinetics, and preliminary efficacy of APG-5918 in patients with solid tumors or hematologic malignancies.

CanariaBio Inc. announces that it has reached 50% of target enrollment of 602 patients for its pivotal Phase III clinical study of its lead product oregovomab, in combination with standard of care chemotherapy for the treatment of front-line advanced ovarian cancer patients.